{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:11:13Z","timestamp":1792069873411,"version":"4.4.0"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Desmoplastic Small Round Cell Tumor (DSRCT) is a highly aggressive pediatric cancer caused by a reciprocal translocation between chromosomes 11 and 22, leading to the formation of the EWSR1::WT1 oncoprotein. DSRCT presents most commonly in the abdominal and pelvic peritoneum and remains refractory to current treatment regimens which include chemotherapy, radiotherapy, and surgery. As a rare cancer, sample and model availability have been a limiting factor to DSRCT research. However, the establishment of rare tumor banks and novel cell lines have recently propelled critical advances in the understanding of DSRCT biology and the identification of potentially promising targeted therapeutics. Here we review model and dataset availability, current understanding of the EWSR1::WT1 oncogenic mechanism, and promising preclinical therapeutics, some of which are now advancing to clinical trials. We discuss efforts to inhibit critical dependencies including NTRK3, EGFR, and CDK4\/6 as well as novel immunotherapy strategies targeting surface markers highly expressed in DSRCT such as B7-H3 or neopeptides either derived from or driven by the fusion oncoprotein. Finally, we discuss the prospect of combination therapies and strategies for prioritizing clinical translation.<\/jats:p>","DOI":"10.3389\/fcell.2024.1442488","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:26:01Z","timestamp":1722313561000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Desmoplastic small round cell tumor: from genomics to targets, potential paths to future therapeutics"],"prefix":"10.3389","volume":"12","author":[{"given":"Justin W.","family":"Magrath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelyn","family":"Espinosa-Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dane A.","family":"Flinchum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruthi Sanjitha","family":"Sampath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai Kong","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean B.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/jco.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"Bioessays"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1226445","DOI":"10.3389\/fimmu.2023.1226445","article-title":"The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition","volume":"14","author":"Anzar","year":"2023","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1186\/1471-2407-13-585","article-title":"The oncogenic properties of EWS\/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts","volume":"13","author":"Bandopadhayay","year":"2013","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"A392","DOI":"10.1136\/jitc-2023-SITC2023.0343","article-title":"343 Defining and therapeutically targeting a fusion-derived public neoantigen in desmoplastic small round cell tumor using T-cell receptor gene therapy","volume":"11","author":"Banks","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/s1470-2045(23)00282-6","article-title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial","volume":"24","author":"Blay","year":"2023","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.3390\/cancers13236072","article-title":"EWSR1-WT1 target genes and therapeutic options identified in a novel DSRCT in vitro model","volume":"13","author":"Bleijs","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1158\/1541-7786.MCR-13-0182-T","article-title":"Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer","volume":"13","author":"Bon","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1278268","DOI":"10.1155\/2017\/1278268","article-title":"Desmoplastic small round blue cell tumor: a review of treatment and potential therapeutic genomic alterations","volume":"2017","author":"Bulbul","year":"2017","journal-title":"Sarcoma"},{"key":"B10","doi-asserted-by":"publisher","first-page":"728","DOI":"10.5858\/2006-130-728-dsrctc","article-title":"Desmoplastic small round cell tumors: cytologic, histologic, and immunohistochemical features","volume":"130","author":"Chang","year":"2006","journal-title":"Archives Pathology Laboratory Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"ra35","DOI":"10.1126\/scisignal.2000369","article-title":"SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis","volume":"2","author":"Cheng","year":"2009","journal-title":"Sci. Signal."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12881-020-01034-w","article-title":"Recurrent secondary genomic alterations in desmoplastic small round cell tumors","volume":"21","author":"Chow","year":"2020","journal-title":"BMC Med. Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/s1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1042\/BCJ20200502","article-title":"Nuts and bolts of the salt-inducible kinases (SIKs)","volume":"478","author":"Darling","year":"2021","journal-title":"Biochem. J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.Cd-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"TPS2596","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS2596","article-title":"A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors","volume":"35","author":"Desantes","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40880-018-0339-3","article-title":"The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial\u2013mesenchymal transition, and immune response","volume":"38","author":"Devecchi","year":"2018","journal-title":"Cancer Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5201","DOI":"10.1038\/onc.2013.462","article-title":"Mode of action of trabectedin in myxoid liposarcomas","volume":"33","author":"Di Giandomenico","year":"2014","journal-title":"Oncogene"},{"key":"B21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1126\/science.2404338","article-title":"Specific expression of a tyrosine kinase gene, blk, in B lymphoid cells","volume":"247","author":"Dymecki","year":"1990","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1104693","DOI":"10.3389\/fonc.2023.1104693","article-title":"Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors","volume":"13","author":"Espinosa-Cotton","year":"2023","journal-title":"Front. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/1120009x.2022.2067706","article-title":"Trabectedin-irinotecan, a potentially promising combination in relapsed desmoplastic small round cell tumor: report of two cases","volume":"35","author":"Ferrari","year":"2023","journal-title":"J. Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00280-006-0280-z","article-title":"Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy","volume":"59","author":"Fine","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2019.10.029","article-title":"SIK2 promotes reprogramming of glucose metabolism through PI3K\/AKT\/HIF-1\u03b1 pathway and Drp1-mediated mitochondrial fission in ovarian cancer","volume":"469","author":"Gao","year":"2020","journal-title":"Cancer Lett."},{"key":"B26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41389-020-0224-1","article-title":"Desmoplastic small round cell tumor is dependent on the EWS-WT1 transcription factor","volume":"9","author":"Gedminas","year":"2020","journal-title":"Oncogenesis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1535-7163.Mct-21-1003","article-title":"Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor","volume":"21","author":"Gedminas","year":"","journal-title":"Mol. Cancer Ther."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1535-7163.MCT-21-1003","article-title":"Lurbinectedin inhibits the EWS\u2013WT1 transcription factor in desmoplastic small round cell tumor","volume":"21","author":"Gedminas","year":"","journal-title":"Mol. cancer Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semcancer.2005.01.005","article-title":"The EWS-WT1 gene fusion in desmoplastic small round cell tumor","volume":"15","author":"Gerald","year":"2005","journal-title":"Semin. Cancer Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1073\/pnas.92.4.1028","article-title":"Characterization of the genomic breakpoint and chimeric transcripts in the EWS-WT1 gene fusion of desmoplastic small round cell tumor","volume":"92","author":"Gerald","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1038\/s41388-021-01811-8","article-title":"Antibody-based cancer therapy","volume":"40","author":"Goydel","year":"2021","journal-title":"Oncogene"},{"key":"B32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1470-2045(07)70175-4","article-title":"Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study","volume":"8","author":"Grosso","year":"2007","journal-title":"lancet Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/annonc\/mdp004","article-title":"Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series","volume":"20","author":"Grosso","year":"2009","journal-title":"Ann. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/ng0311-177","article-title":"New insights into oncogenic stress","volume":"43","author":"Haigis","year":"2011","journal-title":"Nat. Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.1158\/0008-5472.Can-16-0568","article-title":"Lurbinectedin inactivates the ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus","volume":"76","author":"Harlow","year":"2016","journal-title":"Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41389-022-00395-6","article-title":"Salt-inducible kinase 1 is a potential therapeutic target in desmoplastic small round cell tumor","volume":"11","author":"Hartono","year":"2022","journal-title":"Oncogenesis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/j.sempedsurg.2016.09.005","article-title":"Management of desmoplastic small round cell tumor","volume":"25","author":"Hayes-Jordan","year":"2016","journal-title":"Semin. Pediatr. Surg."},{"key":"B38","doi-asserted-by":"publisher","first-page":"12318","DOI":"10.1038\/s41598-020-69015-w","article-title":"Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children's Oncology Group","volume":"10","author":"Hingorani","year":"2020","journal-title":"Sci. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1158\/1535-7163.Mct-21-0758","article-title":"Trastuzumab deruxtecan, antibody-drug conjugate targeting HER2, is effective in pediatric malignancies: a report by the pediatric preclinical testing consortium","volume":"21","author":"Hingorani","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1158\/2159-8290.CD-18-1261","article-title":"The AMPK-related kinases SIK1 and SIK3 mediate key tumor-suppressive effects of LKB1 in NSCLC","volume":"9","author":"Hollstein","year":"2019","journal-title":"Cancer Discov."},{"key":"B41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.suronc.2019.04.002","article-title":"Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients","volume":"29","author":"Honor\u00e9","year":"2019","journal-title":"Surg. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4161\/onci.20226","article-title":"Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma","volume":"1","author":"Hooijkaas","year":"2012","journal-title":"Oncoimmunology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/14737140.2023.2200171","article-title":"Desmoplastic small round cell tumor: from state of the art to future clinical prospects","volume":"23","author":"Hovsepyan","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e2100211","DOI":"10.1200\/po.21.00211","article-title":"Clinical utility of CDK4\/6 inhibitors in sarcoma: successes and future challenges","volume":"6","author":"Hsu","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","article-title":"Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy","volume":"146","author":"Huang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1158\/0008-5472.Can-13-3663","article-title":"EWS-WT1 oncoprotein activates neuronal reprogramming factor ASCL1 and promotes neural differentiation","volume":"74","author":"Kang","year":"2014","journal-title":"Cancer Res."},{"key":"B47","first-page":"27","article-title":"Orphan drugs in development for the treatment of small-cell lung cancer: emerging data on lurbinectedin","volume-title":"Lung cancer: targets and therapy","author":"Kauffmann-Guerrero","year":"2020"},{"key":"B48","doi-asserted-by":"publisher","first-page":"30178","DOI":"10.18632\/oncotarget.4903","article-title":"Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1\/CDK4 pathway inhibition in Ewing sarcoma","volume":"6","author":"Kennedy","year":"2015","journal-title":"Oncotarget"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1038\/sj.onc.1201716","article-title":"The desmoplastic small round cell tumor t(11;22) translocation produces EWS\/WT1 isoforms with differing oncogenic properties","volume":"16","author":"Kim","year":"1998","journal-title":"Oncogene"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.Ccr-20-2584","article-title":"B7-H3: an attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1182\/blood-2008-09-181024","article-title":"Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma","volume":"113","author":"Krejsgaard","year":"2009","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1200\/JCO.1996.14.5.1526","article-title":"Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy","volume":"14","author":"Kushner","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"B53","first-page":"2837","article-title":"Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor","volume":"54","author":"Ladanyi","year":"1994","journal-title":"Cancer Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jpedsurg.2004.09.046","article-title":"Results of multimodal treatment for desmoplastic small round cell tumors","volume":"40","author":"Lal","year":"2005","journal-title":"J. Pediatr. Surg."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1038\/s41467-022-30710-z","article-title":"The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma","volume":"13","author":"Lamhamedi-Cherradi","year":"2022","journal-title":"Nat. Commun."},{"key":"B56","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41698-022-00273-9","article-title":"Harnessing the immunotherapeutic potential of CDK4\/6 inhibitors in melanoma: is timing everything?","volume":"6","author":"Lelliott","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"680126","DOI":"10.1155\/2014\/680126","article-title":"Incidence and outcomes of desmoplastic small round cell tumor: results from the surveillance, epidemiology, and end results database","volume":"2014","author":"Lettieri","year":"2014","journal-title":"J. Cancer Epidemiol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.Ccr-12-1626","article-title":"BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice","volume":"19","author":"Liu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-024-01538-5","article-title":"Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma","volume":"17","author":"Long","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1158\/1078-0432.Ccr-18-2728","article-title":"Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models","volume":"25","author":"Lowery","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"6686702","DOI":"10.1155\/2023\/6686702","article-title":"Genomic breakpoint characterization and transcriptome analysis of metastatic, recurrent desmoplastic small round cell tumor","volume":"2023","author":"Magrath","year":"","journal-title":"Sarcoma"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41389-023-00504-z","article-title":"Transcriptomic analysis identifies B-lymphocyte kinase as a therapeutic target for desmoplastic small round cell tumor cancer stem cell-like cells","volume":"13","author":"Magrath","year":"","journal-title":"Oncogenesis"},{"key":"B64","doi-asserted-by":"publisher","first-page":"565842","DOI":"10.1101\/2023.11.06.565842","article-title":"Enzalutamide induces cytotoxicity in desmoplastic small round cell tumor independent of the androgen receptor","author":"Magrath","year":"","journal-title":"bioRxiv"},{"key":"B65","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s42003-024-06003-0","article-title":"Enzalutamide induces cytotoxicity in desmoplastic small round cell tumor independent of the androgen receptor","volume":"7","author":"Magrath","year":"","journal-title":"Commun. Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1048709","DOI":"10.3389\/fcell.2022.1048709","article-title":"Desmoplastic small round cell tumor cancer stem cell-like cells resist chemotherapy but remain dependent on the EWSR1-WT1 oncoprotein","volume":"10","author":"Magrath","year":"2022","journal-title":"Front. Cell. Dev. Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1158\/0008-5472.Can-23-3334","article-title":"Comprehensive transcriptomic analysis of EWSR1::WT1 targets identifies CDK4\/6 inhibitors as an effective therapy for desmoplastic small round cell tumors","volume":"84","author":"Magrath","year":"","journal-title":"Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"7351","DOI":"10.1073\/pnas.95.13.7351","article-title":"Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase","volume":"95","author":"Malek","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B69","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/mpo.10151","article-title":"Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor","volume":"39","author":"Modak","year":"2002","journal-title":"Med. Pediatr. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"JCO2001974","DOI":"10.1200\/jco.20.01974","article-title":"B7H3-Directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study","volume":"38","author":"Modak","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3389\/fimmu.2019.01835","article-title":"The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment","volume":"10","author":"Monteran","year":"2019","journal-title":"Front. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.3390\/cancers15082354","article-title":"Overcoming the fibrotic fortress in pancreatic ductal adenocarcinoma: challenges and opportunities","volume":"15","author":"Myo Min","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"16823","DOI":"10.3390\/ijms242316823","article-title":"The future of HER2-targeted treatment for osteosarcoma: lessons from the negative trastuzumab deruxtecan results","volume":"24","author":"Nakano","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"32492","DOI":"10.18632\/oncotarget.16477","article-title":"New transcriptional-based insights into the pathogenesis of desmoplastic small round cell tumors (DSRCTs)","volume":"8","author":"Negri","year":"2017","journal-title":"Oncotarget"},{"key":"B75","doi-asserted-by":"publisher","first-page":"zcab033","DOI":"10.1093\/narcan\/zcab033","article-title":"Androgen signaling connects short isoform production to breakpoint formation at Ewing sarcoma breakpoint region 1","volume":"3","author":"Nicholas","year":"2021","journal-title":"Nar. Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/01.lab.0000028059.92642.03","article-title":"Establishment and characterization of a novel human desmoplastic small round cell tumor cell line, JN-DSRCT-1","volume":"82","author":"Nishio","year":"2002","journal-title":"Lab. Investig."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1158\/1078-0432.Ccr-20-2585","article-title":"Therapeutic potential of NTRK3 inhibition in desmoplastic small round cell tumor","volume":"27","author":"Ogura","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e003771","DOI":"10.1136\/jitc-2021-003771","article-title":"Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies","volume":"10","author":"Park","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e002222","DOI":"10.1136\/jitc-2020-002222","article-title":"Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release","volume":"9","author":"Park","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41556-018-0122-3","article-title":"Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism","volume":"20","author":"Patra","year":"2018","journal-title":"Nat. Cell. Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1010428317714196","DOI":"10.1177\/1010428317714196","article-title":"A novel BLK-induced tumor model","volume":"39","author":"Petersen","year":"2017","journal-title":"Tumour Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/leu.2014.192","article-title":"B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)","volume":"28","author":"Petersen","year":"2014","journal-title":"Leukemia"},{"key":"B83","doi-asserted-by":"publisher","first-page":"109010","DOI":"10.1016\/j.celrep.2021.109010","article-title":"Isoform-specific and signaling-dependent propagation of acute myeloid leukemia by Wilms tumor 1","volume":"35","author":"Potluri","year":"2021","journal-title":"Cell. Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.1158\/1078-0432.Ccr-13-1675","article-title":"Dual CDK4\/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma","volume":"19","author":"Rader","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.tem.2018.09.007","article-title":"The salt-inducible kinases: emerging metabolic regulators","volume":"29","author":"Sakamoto","year":"2018","journal-title":"Trends Endocrinol. Metabolism"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.277.5331.1497","article-title":"Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25","volume":"277","author":"Sanchez","year":"1997","journal-title":"Science"},{"key":"B87","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/1078-0432.Ccr-20-2150","article-title":"A self-assembling and disassembling (SADA) bispecific antibody (BsAb) platform for curative two-step pretargeted radioimmunotherapy","volume":"27","author":"Santich","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"9524","DOI":"10.1073\/pnas.91.20.9524","article-title":"Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement","volume":"91","author":"Saouaf","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.4049\/jimmunol.169.3.1611","article-title":"Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma","volume":"169","author":"Sato","year":"2002","journal-title":"J. Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/onc.2008.432","article-title":"Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity","volume":"28","author":"Scaltriti","year":"2009","journal-title":"Oncogene"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3320","DOI":"10.1158\/1078-0432.Ccr-23-0742","article-title":"Results of an open-label, phase ia\/b study of pembrolizumab plus olaratumab in patients with unresectable, locally advanced, or metastatic soft-tissue sarcoma","volume":"29","author":"Sch\u00f6ffski","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/1541-7786.Mcr-20-0722","article-title":"Comprehensive molecular profiling of desmoplastic small round cell tumor","volume":"19","author":"Slotkin","year":"","journal-title":"Mol. Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1158\/1541-7786.Mcr-20-0722","article-title":"Comprehensive molecular profiling of desmoplastic small round cell tumor","volume":"19","author":"Slotkin","year":"","journal-title":"Mol. Cancer Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"11503","DOI":"10.1200\/JCO.2022.40.16_suppl.11503","article-title":"A phase I\/II study of prexasertib in combination with irinotecan in patients with relapsed\/refractory desmoplastic small round cell tumor and rhabdomyosarcoma","volume":"40","author":"Slotkin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"dmm047621","DOI":"10.1242\/dmm.047621","article-title":"Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling","volume":"15","author":"Smith","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"B98","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/jso.25071","article-title":"Desmoplastic small round cell tumor: a nationwide study of a rare sarcoma","volume":"117","author":"Stiles","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1158\/1078-0432.Ccr-18-0202","article-title":"Multimodality treatment of desmoplastic small round cell tumor: chemotherapy and complete cytoreductive surgery improve patient survival","volume":"24","author":"Subbiah","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3889\/oamjms.2018.318","article-title":"HER-2 immunohistochemical expression in bone sarcomas: a new hope for osteosarcoma patients","volume":"6","author":"Tabak","year":"2018","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/bs.acr.2020.04.003","article-title":"EGFR: an essential receptor tyrosine kinase-regulator of cancer stem cells","volume":"147","author":"Talukdar","year":"2020","journal-title":"Adv. Cancer Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.molcel.2018.02.011","article-title":"LKB1, salt-inducible kinases, and MEF2C are linked dependencies in acute myeloid leukemia","volume":"69","author":"Tarumoto","year":"2018","journal-title":"Mol. Cell."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/s1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14656566.2017.1285282","article-title":"The efficacy of trabectedin in treating ovarian cancer","volume":"18","author":"Teplinsky","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"B106","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.3390\/cancers13184704","article-title":"Chimeric antigen receptor T cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma","volume":"13","author":"Terry","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1128\/mcb.20.4.1227-1233.2000","article-title":"The B-cell-specific Src-family kinase Blk is dispensable for B-cell development and activation","volume":"20","author":"Texido","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1158\/1538-7445.Am2024-2851","article-title":"Abstract 2851: characterization of neogenes in desmoplastic small round cell tumors","volume":"84","author":"Truong","year":"2024","journal-title":"Cancer Res."},{"key":"B109","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1186\/s12885-023-10977-1","article-title":"Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing","volume":"23","author":"Truong","year":"2023","journal-title":"BMC Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12885-017-3091-1","article-title":"Mechanism of action of trabectedin in desmoplastic small round cell tumor cells","volume":"17","author":"Uboldi","year":"2017","journal-title":"BMC Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1158\/1078-0432.Ccr-14-0816","article-title":"Molecular pathways: targeting the cyclin D-CDK4\/6 Axis for cancer treatment","volume":"21","author":"VanArsdale","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"3089424","DOI":"10.1155\/2022\/3089424","article-title":"Targeting the FAK-src complex in desmoplastic small round cell tumors, ewing sarcoma, and rhabdomyosarcoma","volume":"2022","author":"van Erp","year":"2022","journal-title":"Sarcoma"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s00432-020-03211-z","article-title":"Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo","volume":"146","author":"van Erp","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1016\/j.molcel.2022.04.019","article-title":"Oncogenic chimeric transcription factors drive tumor-specific transcription, processing, and translation of silent genomic regions","volume":"82","author":"Vibert","year":"2022","journal-title":"Mol. Cell."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3390\/ijms18102111","article-title":"PARP1 in carcinomas and PARP1 inhibitors as antineoplastic drugs","volume":"18","author":"Wang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B118","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2021.02.023","article-title":"Gene fusion neoantigens: emerging targets for cancer immunotherapy","volume":"506","author":"Wang","year":"2021","journal-title":"Cancer Lett."},{"key":"B119","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/08998280.2022.2049581","article-title":"Changing incidence and survival of desmoplastic small round cell tumor in the USA","volume":"35","author":"Waqar","year":"2022","journal-title":"Proc. Bayl Univ. Med. Cent."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/1078-0432.Ccr-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41698-022-00257-9","article-title":"Multi-site desmoplastic small round cell tumors are genetically related and immune-cold","volume":"6","author":"Wu","year":"","journal-title":"NPJ Precis. Oncol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41698-022-00257-9","article-title":"Multi-site desmoplastic small round cell tumors are genetically related and immune-cold","volume":"6","author":"Wu","year":"","journal-title":"npj Precis. Oncol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e21337","DOI":"10.1097\/md.0000000000021337","article-title":"A nationwide analysis of desmoplastic small round cell tumor","volume":"99","author":"Xiang","year":"2020","journal-title":"Med. Baltim."},{"key":"B124","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","article-title":"Immunogenic neoantigens derived from gene fusions stimulate T cell responses","volume":"25","author":"Yang","year":"2019","journal-title":"Nat. Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/jci488","article-title":"Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia","volume":"101","author":"Yotnda","year":"1998","journal-title":"J. Clin. Investig."},{"key":"B126","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/01.Mp.0000056630.76035.F3","article-title":"Immunophenotype of desmoplastic small round cell tumors as detected in cases with EWS-WT1 gene fusion product","volume":"16","author":"Zhang","year":"2003","journal-title":"Mod. Pathol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"e22006","DOI":"10.1200\/JCO.2023.41.16_suppl.e22006","article-title":"Deep multi-omic analyses to identify targetable pathways in desmoplastic small round cell tumor (DSRCT) with opportunities for clinical intervention","volume":"41","author":"Zhu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"dmm049649","DOI":"10.1242\/dmm.049649","article-title":"Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft","volume":"16","author":"Zuco","year":"","journal-title":"Dis. Model. Mech."},{"key":"B129","doi-asserted-by":"publisher","first-page":"dmm049649","DOI":"10.1242\/dmm.049649","article-title":"Effectiveness of irinotecan plus trabectedin on a desmoplastic small round cell tumor patient-derived xenograft","volume":"16","author":"Zuco","year":"","journal-title":"Dis. Models Mech."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1442488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:26:07Z","timestamp":1722313567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1442488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":129,"alternative-id":["10.3389\/fcell.2024.1442488"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2024.1442488","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"article-number":"1442488"}}